Shenyang Xingqi Pharmaceutical Co.,Ltd
SZSE:300573.SZ
150.38 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,943.388 | 1,467.57 | 1,249.855 | 1,027.915 | 688.682 | 542.434 | 431.205 | 360.007 | 339.1 | 287.439 | 254.653 | 218.631 | 212.326 | 190.537 |
| Cost of Revenue
| 421.113 | 340.355 | 265.672 | 225.246 | 185.029 | 145.049 | 119.359 | 93.942 | 84.106 | 85.092 | 62.556 | 29.932 | 25.544 | 20.596 |
| Gross Profit
| 1,522.275 | 1,127.215 | 984.183 | 802.669 | 503.653 | 397.385 | 311.846 | 266.065 | 254.994 | 202.347 | 192.097 | 188.699 | 186.783 | 169.941 |
| Gross Profit Ratio
| 0.783 | 0.768 | 0.787 | 0.781 | 0.731 | 0.733 | 0.723 | 0.739 | 0.752 | 0.704 | 0.754 | 0.863 | 0.88 | 0.892 |
| Reseach & Development Expenses
| 208.675 | 167.297 | 145.614 | 88.447 | 63.193 | 53.967 | 40.968 | 31.837 | 19.586 | 15.947 | 10.27 | 11.19 | 9.724 | 0 |
| General & Administrative Expenses
| 72.741 | 73.705 | 47.547 | 39.156 | 26.552 | 21.827 | 16.078 | 17.305 | 14.956 | 13.721 | 13.227 | 8.892 | 29.654 | 30.019 |
| Selling & Marketing Expenses
| 384.376 | 243.779 | 463.433 | 338.271 | 244.214 | 219.283 | 193.398 | 133.83 | 131.567 | 110.47 | 108.753 | 99.481 | 103.909 | 93.458 |
| SG&A
| 457.117 | 670.906 | 510.981 | 377.428 | 270.766 | 241.11 | 209.476 | 151.136 | 146.523 | 124.191 | 121.981 | 108.373 | 133.564 | 123.476 |
| Other Expenses
| 431.733 | 0.105 | 80.566 | 86.795 | 53.712 | 55.386 | -0.357 | -0.311 | 10.996 | 4.717 | 19.624 | 3.41 | 2.894 | 0.686 |
| Operating Expenses
| 1,097.525 | 858.989 | 737.161 | 552.669 | 387.672 | 350.462 | 294.592 | 215.159 | 196.443 | 166.328 | 159.07 | 135.82 | 137.193 | 126.811 |
| Operating Income
| 424.751 | 276.52 | 250.103 | 248.398 | 105.738 | 37.688 | 11.525 | 46.146 | 53.491 | 21.578 | 18.07 | 51.948 | 50 | 40.921 |
| Operating Income Ratio
| 0.219 | 0.188 | 0.2 | 0.242 | 0.154 | 0.069 | 0.027 | 0.128 | 0.158 | 0.075 | 0.071 | 0.238 | 0.235 | 0.215 |
| Total Other Income Expenses Net
| -29.719 | -11.527 | 2.522 | -4.856 | -3.196 | -1.871 | -0.357 | -0.311 | 6.401 | -7.446 | 19.531 | 3.409 | 3.769 | 0.686 |
| Income Before Tax
| 395.031 | 264.993 | 233.718 | 243.542 | 102.542 | 35.817 | 11.168 | 45.835 | 64.483 | 26.295 | 37.601 | 55.358 | 52.894 | 41.606 |
| Income Before Tax Ratio
| 0.203 | 0.181 | 0.187 | 0.237 | 0.149 | 0.066 | 0.026 | 0.127 | 0.19 | 0.091 | 0.148 | 0.253 | 0.249 | 0.218 |
| Income Tax Expense
| 56.97 | 24.957 | 22.034 | 34.434 | 9.082 | 6.306 | 2.16 | 7.397 | 10.204 | 4.315 | 6.591 | 9.261 | 9.191 | 5.97 |
| Net Income
| 338.062 | 240.036 | 211.684 | 194.702 | 87.979 | 35.894 | 13.659 | 39.437 | 54.279 | 21.98 | 31.01 | 46.097 | 43.703 | 35.637 |
| Net Income Ratio
| 0.174 | 0.164 | 0.169 | 0.189 | 0.128 | 0.066 | 0.032 | 0.11 | 0.16 | 0.076 | 0.122 | 0.211 | 0.206 | 0.187 |
| EPS
| 1.94 | 1.38 | 1.71 | 1.58 | 0.78 | 0.32 | 0.17 | 0.49 | 0.9 | 0.37 | 0.52 | 0.77 | 0.73 | 0.59 |
| EPS Diluted
| 1.93 | 1.38 | 1.71 | 1.58 | 0.77 | 0.32 | 0.17 | 0.49 | 0.9 | 0.37 | 0.52 | 0.77 | 0.73 | 0.59 |
| EBITDA
| 503.245 | 355.242 | 315.5 | 323.878 | 157.843 | 84.12 | 50.084 | 86.089 | 109.95 | 71.352 | 58.824 | 63.446 | 50.055 | 43.131 |
| EBITDA Ratio
| 0.259 | 0.242 | 0.252 | 0.315 | 0.229 | 0.155 | 0.116 | 0.239 | 0.324 | 0.248 | 0.231 | 0.29 | 0.236 | 0.226 |